Norinnova logo hvit. Grafisk element.

Nanospacer

– Bringing nanofluidic technology to the people About the technology The Nanospacer is a specially designed microscope coverslip that allows nanoscale particle characterisation. Nanofluidic technology, including analysis of proteins and binding events on a single-molecule level, will open doors to the next generation of nanomedicines, nanoparticles and nanomachinery. Resources Research Council Norway commercialisation grant Patent […]

New therapeutic for liver disease, NASH

An unmet medical need Non-alcoholic steatohepatitis (NASH) is an advanced form of fatty liver disease that is expected to become the major cause of liver transplantation in the US by 2025. There is an enormous unmet medical need to treat the disease because of its high prevalence and lack of treatment options: there are currently […]

Tau-on-Chip: nanofluidic amyloid aggregation within seconds

About the technology On-demand production of protein aggregates: We produce oligomers and fibrils within seconds in a nanofluidic environment. This has potential for high throughput screening of drug candidates, automated in-vitro assays, and binding assays with single molecule sensitivity. Areas of application We envisage producing the nanofluidic Tau-on- Chip devices for use in drug development, […]

MicroRNAs for reduced bleeding risk in Venous thromboembolism patients

– MicroRNAs for risk assessment and treatment of venous thromboembolism The challenge Venous thromboembolism (VTE) is a highly prevalent disease, affecting around 1.1 million individuals in Europe each year, with 540,000 associated deaths. No modifiable risk-factors have been identified yet. The current anti-coagulant treatment is associated with serious bleeding risks. We therefore need to find […]